Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Steve's Channelling Thread -- Ignore unavailable to you. Want to Upgrade?

To: Justa Werkenstiff who wrote (29011)	9/28/2001 8:04:56 AM
From: wgh613	Respond to of 30051

MLNM,ILXO could get attention: BERLIN, Sept. 28 /PRNewswire/ -- Schering AG, Germany (NYSE: SHR - news; FSE: SCH), announced today that Campath® (alemtuzumab), a humanized monoclonal antibody, was successfully tested in a clinical trial for the treatment of T-PLL (T-cell prolymphocytic leukemia). The new data strongly indicate that Campath® can be effective as first-line therapy for T-PLL, which would represent another step forward in Schering's strategy to strengthen its role in different indications in the field of hematological oncology. Campath® was approved in the US and Europe (trade name in Europe: MabCampath(TM)) earlier this year and is currently available to patients with B-cell chronic lymphocytic leukemia (B-CLL), who have been treated with alkylating agents and have failed fludarabine therapy. Campath® for B-CLL was developed by M&I Partners, a 50-50 joint venture of Millennium Pharmaceuticals, Inc., (Nasdaq: MLNM - news) and ILEX Oncology, Inc., (Nasdaq: ILXO - news), and Schering AG, Germany. In the US, Campath is marketed by Berlex Laboratories, a US subsidiary of Schering AG. T-PLL is a rare, aggressive malignancy which confronts patients with a median survival time of seven months. Chemotherapy has a low success rate with 6-10% CR (Complete Remission). The majority (76 %) of patients who received Campath® responded to therapy with a 60% CR. By producing remissions in more than two thirds of patients, Campath® could be a very effective agent in the fight against T-PLL. The data were published by Dearden CE et al, Blood 2001; 98: 1721-6. Campath® binds to CD52+, an antigen that is present on the surface of certain leukemic lymphocytes and highly expressed on T-PLL cells. It induces antibody-dependent lysis (killing) following binding. This results in the removal of the malignant lymphocytes from the blood, bone marrow, and other affected organs. Schering AG is a research-based pharmaceutical company. Its activities are focused on four business areas: Fertility Control & Hormone Therapy, Diagnostics & Radiopharmaceuticals, Dermatology as well as Specialized Therapeutics for disabling diseases, e.g. multiple sclerosis, leukemia and solid tumors. As a global player with innovative products Schering AG aims for leading positions in specialized markets worldwide. With in-house R&D and supported by an excellent global network with external partners, Schering AG is securing a promising product pipeline. Using new ideas, Schering AG aims to make a recognized contribution to medical progress and strives to improve the quality of life. An electronic version of this news release -- as well as additional information about Schering AG -- is available at www.schering.de/eng ...

To: Justa Werkenstiff who wrote (29011)	9/28/2001 8:52:08 AM
From: LTK007	Read Replies (1) \| Respond to of 30051

Merrill cuts Sales and Profits for MSFT ,but futures don't blink--futures have a momentum.Max

To: Justa Werkenstiff who wrote (29011)	9/30/2001 6:52:58 PM
From: Justa Werkenstiff	Read Replies (1) \| Respond to of 30051

Said this a few days ago about the Taliban: "They are just waiting and waiting for the evil US to put on a fireworks show. They will start seeing shadows soon. They will beg us to strike because they cannot stand the wait." News today: Sunday September 30 2:33 PM ET Taliban Leader: U.S. Won't Attack By AMIR SHAH, Associated Press Writer KABUL, Afghanistan (AP) - The leader of Afghanistan's hard-line Taliban told his people Sunday not to worry about U.S. attacks on their country because Americans are cowards. ``Americans don't have the courage to come here,'' Mullah Mohammed Omar said in an interview broadcast by Taliban-controlled Kabul Radio. He urged Afghans to remain calm and go about their business without trying to flee cities that might be targets of U.S. air strikes. The United States has threatened military action against Afghanistan unless the Taliban hand over Osama bin Laden, whom the Americans consider the mastermind of the Sept. 11 terrorist attacks on the World Trade Center and the Pentagon. Bin Laden has denied any role in the attacks, and Afghan authorities say the United States has offered no proof to back up its allegations against the exiled Saudi dissident. The Taliban said Sunday that bin Laden in under their ``control'' in a secret location and offered negotiations with the United States, something Washington refused. During the interview, Omar repeatedly warned the United States to ``think and think again'' about attacking his country, which drove out Soviet invaders with U.S. assistance in the 1979-1989 war. ``If you attack us, there will be no difference between you and the Russians,'' the Taliban leader said. ``We are peace-loving and we hate terrorism. The murder of one person is the same as the murder of all humanity.'' Omar instead blamed the Sept. 11 attacks on American policies - without stating which ones. ``Whatever the Americans are facing is the result of their policies,'' he said, ``and the U.S. authorities should review their policies and should not unnecessarily create problems for Muslims.'' Omar defended the Taliban's stewardship of this country since they took power in 1996. ``Before the formation of the Taliban government, there was complete anarchy,'' he said. ``Nobody was safe. But now, there is complete peace in our country and there is no room for communism.'' Omar also discounted any role for the former king, Mohammad Zahir Shah, who lives in exile in Rome. The 86-year-old former monarch told a U.S. congressional delegation Sunday that he was by America's side in the fight against terrorism and would back a U.S.-led liberation force to oust the Taliban. ``He should be ashamed of what he is doing,'' Omar said of the former king. ``He should be ashamed.''